Abbott Laboratories Stock News

The latest "Infectious Disease Treatment Market" report evaluates the current market size and describes necessary factors like prime manufacturers, production worth, market share, key regions, and growth rate. It also focuses more on current statistics on the global Infectious Disease

Dublin, Dec. 13, 2021 (GLOBE NEWSWIRE) -- The "Clinical Nutrition Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering.

The study of Hematology Products market is a compilation of the market of Hematology Products broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The

Major helicobacter pylori testing market players include Abbott Laboratories, Avanos Corporate, Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health, Exalenz Bioscience Ltd., Gulf Coast Scienti

According to the new market research report "ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) - Forecast

Harel Insurance Investments & Financial Services Ltd. cut its position in Abbott Laboratories (NYSE:ABT) by 72.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,481 shares of the healthcare product makers stock after selling 3,800 shares during the quarter. Harel Insurance []

The stock price of Abbott Laboratories (NYSE: ABT) increased by 1.39% in the previous trading session. This is why it happened.

J.W. Cole Advisors Inc. grew its holdings in Abbott Laboratories (NYSE:ABT) by 6.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,087 shares of the healthcare product maker’s stock after purchasing an additional 1,178 shares during the quarter. J.W. Cole Advisors […]

Zoetis, Pentair, Johnson Controls International, and Abbott Laboratories were among the many companies that declared dividend increases this week.

Boston Trust Walden Corp grew its stake in Abbott Laboratories (NYSE:ABT) by 3.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 57,480 shares of the healthcare product makers stock after buying an additional 2,078 shares during the period. Boston Trust Walden Corps holdings []

Abbott Laboratories (NYSE:ABT) declared that its Board of Directors has approved a share buyback plan on Friday, December 10th, RTT News reports. The company plans to repurchase $5.00 billion in shares. This repurchase authorization authorizes the healthcare product maker to purchase up to 2.1% of its stock through open market purchases. Stock repurchase plans are []

Global Bioabsorbable Stents Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international economy. The Global Bioabsorbable Stents Market Report offers vital insights to

West Family Investments Inc. increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 11.9% in the third quarter, HoldingsChannel reports. The firm owned 6,875 shares of the healthcare product makers stock after buying an additional 732 shares during the period. West Family Investments Inc.s holdings in Abbott Laboratories were worth $812,000 as of its []

Abbott Laboratories (NYSE:ABT) declared a quarterly dividend on Friday, December 10th, RTT News reports. Stockholders of record on Friday, January 14th will be paid a dividend of 0.47 per share by the healthcare product maker on Monday, February 15th. This represents a $1.88 annualized dividend and a dividend yield of 1.40%. This is a positive []

Relyea Zuckerberg Hanson LLC grew its holdings in Abbott Laboratories (NYSE:ABT) by 21.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,729 shares of the healthcare product makers stock after acquiring an additional 478 shares during the quarter. Relyea Zuckerberg Hanson LLCs holdings in []